MeSH term
Frequency | Condition_Probility | Animals | 130 | 0.0 |
CHO Cells | 5 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Genetic Vectors | 5 | 0.0 |
Hamsters | 7 | 0.0 |
Hela Cells | 6 | 0.0 |
Humans | 196 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 141 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Transfection | 13 | 0.0 |
Aged | 14 | 0.0 |
Glucokinase/chemistry/*metabolism | 2 | 100.0 |
Glucose/*pharmacology | 3 | 3.0 |
Islets of Langerhans/*enzymology | 7 | 46.0 |
Protein Conformation | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 13 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 82 | 0.0 |
Base Sequence | 34 | 0.0 |
Cell Line | 21 | 0.0 |
*Chromosome Mapping | 5 | 0.0 |
Cohort Studies | 3 | 0.0 |
Diabetes Mellitus, Type 2/enzymology/*genetics | 4 | 17.0 |
Genes, Reporter | 4 | 0.0 |
Genotype | 7 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Mice | 26 | 0.0 |
Molecular Sequence Data | 55 | 0.0 |
Rats | 58 | 0.0 |
Recombinant Proteins/metabolism | 5 | 0.0 |
Reference Values | 7 | 0.0 |
Sequence Deletion | 3 | 0.0 |
Adolescent | 13 | 0.0 |
Adult | 34 | 0.0 |
Analysis of Variance | 3 | 0.0 |
Comparative Study | 24 | 0.0 |
Female | 59 | 0.0 |
Male | 80 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Chromosome Banding | 3 | 0.0 |
English Abstract | 18 | 0.0 |
Haplotypes | 2 | 0.0 |
Homozygote | 3 | 0.0 |
Infant, Newborn | 4 | 0.0 |
Insulin/blood | 5 | 0.0 |
Mutation | 11 | 0.0 |
Amino Acid Sequence | 39 | 0.0 |
COS Cells | 5 | 0.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
*Drosophila Proteins | 2 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Protein Transport | 2 | 0.0 |
src Homology Domains | 2 | 0.0 |
Cells, Cultured | 25 | 0.0 |
Nerve Tissue Proteins/*metabolism | 3 | 1.0 |
Precipitin Tests | 3 | 0.0 |
Receptors, N-Methyl-D-Aspartate/*metabolism | 2 | 18.0 |
Rats, Mutant Strains | 5 | 7.0 |
Rats, Wistar | 22 | 1.0 |
Cell-Free System | 2 | 0.0 |
Open Reading Frames | 2 | 0.0 |
Action Potentials/physiology | 2 | 4.0 |
Glucokinase/metabolism | 5 | 83.0 |
Glycolysis | 2 | 3.0 |
Neurons/*physiology | 2 | 1.0 |
Potassium Channels/physiology | 3 | 13.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Immunohistochemistry | 7 | 0.0 |
Middle Aged | 31 | 0.0 |
Age Factors | 2 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Blood Glucose | 2 | 2.0 |
Body Weight/drug effects | 2 | 1.0 |
Cell Division/drug effects | 3 | 0.0 |
Disease Models, Animal | 13 | 0.0 |
Longitudinal Studies | 2 | 0.0 |
Gene Expression Regulation, Enzymologic | 5 | 0.0 |
Glucokinase/*genetics/*metabolism | 2 | 100.0 |
Hepatocytes/metabolism | 2 | 2.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Blotting, Western | 6 | 0.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Kinetics | 17 | 0.0 |
Phosphorylation | 8 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Time Factors | 4 | 0.0 |
Up-Regulation | 2 | 0.0 |
Diabetes Mellitus, Type 2/*metabolism | 3 | 6.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Fatty Acids, Nonesterified/blood | 2 | 1.0 |
Liver/enzymology | 6 | 1.0 |
Glucose/*metabolism | 11 | 7.0 |
Homeostasis | 4 | 1.0 |
Signal Transduction | 2 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Postoperative Complications | 3 | 2.0 |
Prognosis | 4 | 0.0 |
*Radiosurgery | 2 | 16.0 |
Retrospective Studies | 3 | 0.0 |
Survival Analysis | 2 | 0.0 |
Treatment Outcome | 5 | 0.0 |
*Ca(2+)-Calmodulin Dependent Protein Kinase | 2 | 18.0 |
Models, Molecular | 4 | 0.0 |
Protein Binding | 6 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Sequence Homology, Amino Acid | 11 | 0.0 |
Cercopithecus aethiops | 16 | 1.0 |
Glycosylation | 5 | 0.0 |
Vero Cells | 18 | 8.0 |
Viral Proteins/*physiology | 4 | 12.0 |
Forskolin/pharmacology | 3 | 0.0 |
Glucokinase/*metabolism | 6 | 85.0 |
Models, Biological | 5 | 0.0 |
Adenoviridae/genetics | 4 | 0.0 |
Blood Glucose/analysis | 4 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Glucokinase/*genetics/metabolism | 4 | 100.0 |
Mice, Inbred C57BL | 7 | 0.0 |
Phenotype | 9 | 0.0 |
Chromosome Mapping | 20 | 0.0 |
Diabetes Mellitus, Type 2/*genetics | 7 | 4.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Pedigree | 11 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Glycerol Kinase/chemistry/*deficiency/*genetics | 2 | 100.0 |
Mutation, Missense | 2 | 0.0 |
X Chromosome/genetics | 3 | 1.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 2 | 0.0 |
Biological Transport/drug effects | 2 | 0.0 |
Glucose/metabolism | 7 | 2.0 |
*Insulin Resistance | 2 | 1.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
Blood Glucose/metabolism | 11 | 1.0 |
Body Weight | 5 | 0.0 |
*Carrier Proteins | 5 | 0.0 |
Fasting | 2 | 0.0 |
Glucose Tolerance Test | 7 | 1.0 |
Rats, Sprague-Dawley | 6 | 0.0 |
Tumor Cells, Cultured | 9 | 0.0 |
Expressed Sequence Tags | 2 | 0.0 |
Genetic Markers | 6 | 0.0 |
*Linkage (Genetics) | 4 | 0.0 |
Microsatellite Repeats | 2 | 0.0 |
Models, Genetic | 3 | 0.0 |
Polymorphism, Genetic | 4 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Liver/metabolism | 2 | 0.0 |
Plasmids/metabolism | 3 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Tomography, X-Ray Computed | 3 | 0.0 |
Child | 14 | 0.0 |
Child, Preschool | 12 | 0.0 |
Exons/genetics | 3 | 0.0 |
Follow-Up Studies | 6 | 0.0 |
Glycerol Kinase/*deficiency/genetics/metabolism | 2 | 100.0 |
Heterozygote | 7 | 0.0 |
*Mutation | 5 | 0.0 |
Diabetes Mellitus, Type 2/*genetics/metabolism | 2 | 18.0 |
Gene Targeting | 2 | 0.0 |
Hyperglycemia/genetics | 2 | 40.0 |
Mice, Knockout | 4 | 0.0 |
Mice, Transgenic | 6 | 0.0 |
Protein Processing, Post-Translational | 3 | 0.0 |
Cloning, Molecular | 14 | 0.0 |
DNA, Complementary | 4 | 0.0 |
Glycerol Kinase/*genetics | 5 | 83.0 |
Glucokinase/*genetics | 6 | 17.0 |
Magnetic Resonance Imaging | 4 | 0.0 |
Radiosurgery/*instrumentation | 2 | 50.0 |
Macromolecular Substances | 3 | 0.0 |
Eye/virology | 3 | 60.0 |
Mice, Inbred BALB C | 7 | 0.0 |
Viral Proteins/*immunology | 3 | 8.0 |
Virus Replication | 5 | 0.0 |
Alleles | 4 | 0.0 |
Lipids/metabolism | 2 | 0.0 |
Muscles/metabolism | 2 | 2.0 |
Point Mutation | 4 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Cataract/*enzymology/genetics | 2 | 100.0 |
Gene Expression | 12 | 0.0 |
Disease Progression | 2 | 0.0 |
Reoperation | 2 | 1.0 |
Cattle | 6 | 0.0 |
Rabbits | 3 | 0.0 |
Viral Envelope Proteins/genetics/metabolism/*physiology | 2 | 100.0 |
Plant Extracts/toxicity | 2 | 40.0 |
*Plants, Medicinal | 2 | 2.0 |
Down-Regulation | 2 | 0.0 |
*Membrane Fusion | 4 | 10.0 |
Viral Envelope Proteins/*physiology | 2 | 11.0 |
Binding Sites | 6 | 0.0 |
Consensus Sequence | 2 | 0.0 |
Sequence Alignment | 6 | 0.0 |
Transformation, Genetic | 2 | 1.0 |
Introns/genetics | 2 | 0.0 |
Lod Score | 2 | 0.0 |
Mutation, Missense/*genetics | 2 | 1.0 |
Insulin/blood/*secretion | 3 | 6.0 |
Monosaccharide Transport Proteins/metabolism | 2 | 5.0 |
Italy | 2 | 0.0 |
Nerve Tissue Proteins/metabolism | 3 | 1.0 |
Potassium Channels/*metabolism | 3 | 7.0 |
*Potassium Channels, Inwardly Rectifying | 2 | 4.0 |
Xenopus | 2 | 0.0 |
Biological Transport | 3 | 0.0 |
Liver/*enzymology | 6 | 1.0 |
Proteins/*physiology | 2 | 1.0 |
Enzyme Activation | 4 | 0.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
Viral Proteins/*genetics | 4 | 5.0 |
Diabetes Mellitus, Type 2/*physiopathology | 2 | 6.0 |
Insulin/*secretion | 8 | 10.0 |
Islets of Langerhans/*secretion | 2 | 18.0 |
Rats, Inbred Strains | 9 | 1.0 |
Signal Transduction/physiology | 2 | 0.0 |
Glucokinase/genetics/*metabolism | 4 | 100.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Liver/enzymology/*metabolism | 2 | 5.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 2 | 0.0 |
Glucose/pharmacology | 3 | 2.0 |
In Vitro | 9 | 0.0 |
*Point Mutation | 5 | 0.0 |
Islets of Langerhans/enzymology | 3 | 75.0 |
Herpesvirus 1, Human/*immunology | 2 | 15.0 |
Vaccination | 4 | 2.0 |
Cell Line, Transformed | 2 | 0.0 |
Plaque Assay | 5 | 7.0 |
Recombination, Genetic | 5 | 0.0 |
Nucleoside-Phosphate Kinase/*metabolism | 2 | 28.0 |
Genes, Viral | 2 | 0.0 |
Calcium/*metabolism | 3 | 0.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Neutralization Tests | 2 | 0.0 |
RNA, Messenger | 2 | 0.0 |
Cell Membrane/metabolism | 3 | 0.0 |
Cosmids | 5 | 1.0 |
Deoxyribonucleases, Type II Site-Specific | 2 | 0.0 |
Acute Disease | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
Escherichia coli/enzymology/genetics | 2 | 3.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Substrate Specificity | 2 | 0.0 |
DNA Primers | 9 | 0.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Polymerase Chain Reaction | 18 | 0.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Viral Proteins/genetics/*metabolism | 4 | 7.0 |
Potassium Chloride/pharmacology | 2 | 3.0 |
Evolution, Molecular | 2 | 0.0 |
Linkage (Genetics) | 5 | 0.0 |
Mice/*genetics | 4 | 1.0 |
Gene Expression Regulation | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
*Genetic Heterogeneity | 2 | 1.0 |
Glycerol/metabolism | 2 | 5.0 |
Glycerol Kinase/deficiency/*genetics | 3 | 60.0 |
Infant | 5 | 0.0 |
Chick Embryo | 2 | 0.0 |
DNA, Viral | 3 | 1.0 |
Giant Cells | 3 | 5.0 |
Insulin/metabolism | 3 | 2.0 |
Gene Deletion | 4 | 0.0 |
Muscular Dystrophies/*genetics | 5 | 5.0 |
Syndrome | 3 | 0.0 |
*X Chromosome | 12 | 1.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
*Cell Fusion | 2 | 5.0 |
Islets of Langerhans/*metabolism | 4 | 7.0 |
Liver/*metabolism | 2 | 0.0 |
Uridine Diphosphate Glucose/metabolism | 2 | 28.0 |
Mutagenesis | 2 | 0.0 |
Virion/physiology | 2 | 8.0 |
*Disease Models, Animal | 2 | 0.0 |
Insulin Resistance | 2 | 1.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Plasmids | 2 | 0.0 |
Species Specificity | 4 | 0.0 |
Immunity, Cellular | 3 | 0.0 |
Calcium/metabolism | 3 | 0.0 |
Electric Conductivity | 6 | 3.0 |
Membrane Potentials | 2 | 0.0 |
Insulin/secretion | 2 | 3.0 |
Glycerolphosphate Dehydrogenase/*genetics | 2 | 33.0 |
Mitochondria/*enzymology | 2 | 1.0 |
Restriction Mapping | 5 | 0.0 |
Glucokinase/biosynthesis/*genetics | 2 | 66.0 |
*Promoter Regions (Genetics) | 5 | 0.0 |
Diabetes Mellitus, Experimental/*enzymology | 2 | 100.0 |
Chronic Disease | 2 | 0.0 |
Virus Latency | 2 | 3.0 |
Blood Glucose/drug effects/metabolism | 3 | 12.0 |
Lactates/blood | 2 | 2.0 |
Potassium/physiology | 2 | 28.0 |
*Chromosome Deletion | 6 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Exons | 4 | 0.0 |
Fibroblasts/enzymology | 3 | 1.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Genome, Viral | 2 | 1.0 |
Herpesvirus 1, Human/*genetics/metabolism | 2 | 40.0 |
Horses | 2 | 1.0 |
Protein Biosynthesis | 2 | 0.0 |
Glucose-6-Phosphatase/metabolism | 2 | 28.0 |
*Alternative Splicing | 2 | 0.0 |
Gene Library | 5 | 0.0 |
Organ Specificity | 3 | 0.0 |
Conserved Sequence | 2 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
GTP-Binding Proteins/*physiology | 5 | 4.0 |
Myocardium/*metabolism | 3 | 1.0 |
Cell Fusion | 4 | 1.0 |
Endoplasmic Reticulum/metabolism | 2 | 0.0 |
Herpesvirus 1, Human/genetics/*physiology | 2 | 13.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Electrophysiology | 2 | 0.0 |
Hexokinase/metabolism | 4 | 26.0 |
Diabetes Mellitus, Type 2/metabolism | 2 | 7.0 |
Glucose/*metabolism/pharmacology | 2 | 20.0 |
Enzyme Inhibitors/metabolism | 2 | 0.0 |
Viral Envelope Proteins/genetics/*metabolism | 3 | 11.0 |
Virion/*metabolism | 2 | 9.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Myocardium/metabolism | 2 | 0.0 |
Pertussis Toxin | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Islets of Langerhans/*drug effects/secretion | 2 | 50.0 |
Cell Fusion/*physiology | 2 | 40.0 |
Simplexvirus/genetics/*growth & development | 2 | 100.0 |
Drug Interactions | 2 | 0.0 |
Adrenal Insufficiency/congenital/*genetics | 2 | 40.0 |
Chromosomes, Fungal | 3 | 4.0 |
Genome, Human | 3 | 0.0 |
Endocytosis | 2 | 0.0 |
DNA/genetics | 3 | 0.0 |
Guinea Pigs | 6 | 0.0 |
Potassium/*metabolism | 6 | 12.0 |
Chromosome Deletion | 2 | 0.0 |
Glycerol Kinase/*deficiency | 2 | 33.0 |
DNA-Binding Proteins/*metabolism | 2 | 0.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Radiotherapy Dosage | 2 | 1.0 |
Blotting, Southern | 3 | 0.0 |
Glycerol Kinase/*deficiency/genetics | 3 | 75.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
Galactose/metabolism | 2 | 6.0 |
Guanosine 5'-O-(3-Thiotriphosphate) | 3 | 17.0 |
Guanosine Triphosphate/analogs & derivatives/pharmacology | 2 | 22.0 |
Thionucleotides/pharmacology | 2 | 3.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
Galactokinase/*blood | 2 | 100.0 |
Potassium Channels/*physiology | 2 | 6.0 |
Receptors, Muscarinic/*physiology | 3 | 13.0 |
DNA/*genetics | 2 | 0.0 |
DNA Probes | 2 | 0.0 |
Phosphotransferases/*deficiency | 6 | 35.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Karyotyping | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Kallikreins/*blood | 3 | 37.0 |
GTP-Binding Proteins/*pharmacology | 3 | 100.0 |
Heart/*physiology | 2 | 3.0 |
Ion Channels/drug effects/*physiology | 4 | 33.0 |
Mice, Obese | 2 | 4.0 |
Diabetes Mellitus, Type 2/*complications | 2 | 5.0 |
Diet | 2 | 0.0 |
Thyrotropin/blood | 2 | 0.0 |
Thyroxine/blood | 2 | 0.0 |
Triiodothyronine/blood | 2 | 0.0 |
Models, Animal | 2 | 0.0 |
